Here is a brief preview of this blast: On Monday, April 22, the CHMP Agenda for April was released. Of note, obe-cel (Autolus’s CD19 CAR-T) was included in the “Start of Procedure for New Application” section for the treatment of adult patients with r/r B-ALL.
About The Author
The Celltelligence Team
Content Leads & Contributors
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.